134 related articles for article (PubMed ID: 23448477)
1. The use of bifunctional NOP/mu and NOP receptor selective compounds for the treatment of pain, drug abuse, and psychiatric disorders.
Toll L
Curr Pharm Des; 2013; 19(42):7451-60. PubMed ID: 23448477
[TBL] [Abstract][Full Text] [Related]
2. NOP-Related Mechanisms in Pain and Analgesia.
Toll L; Ozawa A; Cippitelli A
Handb Exp Pharmacol; 2019; 254():165-186. PubMed ID: 31119465
[TBL] [Abstract][Full Text] [Related]
3. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
Zaveri NT
Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
[TBL] [Abstract][Full Text] [Related]
4. Role of Nociceptin/Orphanin FQ-NOP Receptor System in the Regulation of Stress-Related Disorders.
Ubaldi M; Cannella N; Borruto AM; Petrella M; Micioni Di Bonaventura MV; Soverchia L; Stopponi S; Weiss F; Cifani C; Ciccocioppo R
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884757
[TBL] [Abstract][Full Text] [Related]
5. The NOP Receptor System in Neurological and Psychiatric Disorders: Discrepancies, Peculiarities and Clinical Progress in Developing Targeted Therapies.
Toll L; Cippitelli A; Ozawa A
CNS Drugs; 2021 Jun; 35(6):591-607. PubMed ID: 34057709
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
Kiguchi N; Kishioka S; Ko MC
Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
[TBL] [Abstract][Full Text] [Related]
7. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).
Bird MF; Cerlesi MC; Brown M; Malfacini D; Vezzi V; Molinari P; Micheli L; Di Cesare Mannelli L; Ghelardini C; Guerrini R; Calò G; Lambert DG
PLoS One; 2016; 11(6):e0156897. PubMed ID: 27272042
[TBL] [Abstract][Full Text] [Related]
8. Nociceptin/orphanin FQ and its receptor--potential targets for pain therapy?
Zeilhofer HU; Calò G
J Pharmacol Exp Ther; 2003 Aug; 306(2):423-9. PubMed ID: 12721334
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
Khroyan TV; Polgar WE; Orduna J; Montenegro J; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Nov; 339(2):687-93. PubMed ID: 21859931
[TBL] [Abstract][Full Text] [Related]
10. NOP-Related Mechanisms in Substance Use Disorders.
Ciccocioppo R; Borruto AM; Domi A; Teshima K; Cannella N; Weiss F
Handb Exp Pharmacol; 2019; 254():187-212. PubMed ID: 30968214
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
Kiguchi N; Ding H; Ko MC
J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240
[TBL] [Abstract][Full Text] [Related]
12. NOP Ligands for the Treatment of Anxiety and Mood Disorders.
Gavioli EC; Holanda VAD; Ruzza C
Handb Exp Pharmacol; 2019; 254():233-257. PubMed ID: 30535941
[TBL] [Abstract][Full Text] [Related]
13. Nociceptin/orphanin FQ acts as a functional antagonist of corticotropin-releasing factor to inhibit its anorectic effect.
Ciccocioppo R; Cippitelli A; Economidou D; Fedeli A; Massi M
Physiol Behav; 2004 Aug; 82(1):63-8. PubMed ID: 15234592
[TBL] [Abstract][Full Text] [Related]
14. Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.
Toll L; Bruchas MR; Calo' G; Cox BM; Zaveri NT
Pharmacol Rev; 2016 Apr; 68(2):419-57. PubMed ID: 26956246
[TBL] [Abstract][Full Text] [Related]
15. Antinociceptive effects of spinally administered nociceptin/orphanin FQ and its N-terminal fragments on capsaicin-induced nociception.
Katsuyama S; Mizoguchi H; Komatsu T; Sakurada C; Tsuzuki M; Sakurada S; Sakurada T
Peptides; 2011 Jul; 32(7):1530-5. PubMed ID: 21672568
[TBL] [Abstract][Full Text] [Related]
16. Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands.
Gavioli EC; Calo' G
Naunyn Schmiedebergs Arch Pharmacol; 2006 Feb; 372(5):319-30. PubMed ID: 16491387
[TBL] [Abstract][Full Text] [Related]
17. Anxiolytic-like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats.
Vitale G; Arletti R; Ruggieri V; Cifani C; Massi M
Peptides; 2006 Sep; 27(9):2193-200. PubMed ID: 16730097
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.
Meyer ME; Doshi A; Yasuda D; Zaveri NT
AAPS J; 2021 May; 23(3):68. PubMed ID: 33974173
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
Lin AP; Ko MC
ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
[TBL] [Abstract][Full Text] [Related]
20. Orphanin FQ/nociceptin potentiates [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin-Induced mu-opioid receptor phosphorylation.
Ozsoy HZ; Thakker DR; Standifer KM
Mol Pharmacol; 2005 Aug; 68(2):447-56. PubMed ID: 15890842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
